药品注册申请号:021252
申请类型:NDA (新药申请)
申请人:ABBVIE
申请人全名:ABBVIE INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 CANASA MESALAMINE SUPPOSITORY;RECTAL 500MG No No None 2001/01/05 2001/01/05 Discontinued
002 CANASA MESALAMINE SUPPOSITORY;RECTAL 1GM Yes Yes AB 2004/11/05 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/10/24 SUPPL-30(补充) Approval Labeling STANDARD ;Orphan
2022/11/16 SUPPL-29(补充) Approval Labeling STANDARD
2021/11/01 SUPPL-28(补充) Approval Labeling STANDARD ;Orphan
2020/10/01 SUPPL-25(补充) Approval Labeling STANDARD ;Orphan
2017/07/27 SUPPL-23(补充) Approval Labeling STANDARD ;Orphan
2016/09/02 SUPPL-14(补充) Approval Efficacy PRIORITY ;Orphan
2014/07/30 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
2014/01/02 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
2013/12/24 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
2013/12/17 SUPPL-20(补充) Approval Labeling STANDARD
2013/05/03 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
2013/02/06 SUPPL-13(补充) Approval Labeling UNKNOWN
2008/05/23 SUPPL-9(补充) Approval Manufacturing (CMC) N/A
2006/06/08 SUPPL-7(补充) Approval Labeling STANDARD
2004/11/05 SUPPL-5(补充) Approval Efficacy STANDARD
2004/09/23 SUPPL-6(补充) Approval Labeling STANDARD
2003/10/14 SUPPL-2(补充) Approval Labeling STANDARD
2001/01/05 ORIG-1(原始申请) Approval Type 5 - New Formulation or New Manufacturer PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
002 8217083 2028/06/06 Y 2013/05/24 PDF格式
8436051 2028/06/06 Y 2013/05/24 PDF格式
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 M-187 2019/09/02**本条是由Drugfuture回溯的历史信息**
002 D-92 2007/11/05**本条是由Drugfuture回溯的历史信息**
NS 2007/11/05**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:MESALAMINE 剂型/给药途径:SUPPOSITORY;RECTAL 规格:1GM 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021252 002 NDA CANASA MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription Yes Yes AB 2004/11/05 ABBVIE
204354 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2015/11/24 MYLAN
207448 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2019/04/19 PHARM SOURCING
202065 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2019/06/12 SANDOZ
208362 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2019/06/21 AMRING PHARMS
210509 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Discontinued No No AB 2020/01/02 AMNEAL
208953 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2020/02/12 ZYDUS PHARMS
213377 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2020/03/19 ANNORA PHARMA
205654 001 ANDA MESALAMINE MESALAMINE SUPPOSITORY;RECTAL 1GM Prescription No No AB 2020/08/14 ACTAVIS MID ATLANTIC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database